Transitions From Parenteral Prostacyclin Analogues to Selexipag in Patients With Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive illness that may require therapy with parenteral prostacyclin pathway agents (PPA) (epoprostenol and treprostinil). These parenteral PPA ' s are continuous ambulatory infusions that require a high level of skill and knowledge to maintain safety and effectiveness. Depending on the clinical context, transition to oral prostacyclin receptor agonist therapy (selexipag) is sometimes pursued. To prevent abrupt withdrawal from parenteral PPA's, overlap transitions are typically used. This report describes 35 inpatient, rapid transitions from parenteral PPA's to oral selexipag. Planned hospital admissions for transition were common ( n = 27, 77%), and all patients successfully transitioned without a return to parenteral PPA's in the immediate post‐transition period. Most patients transitioned due to difficulties with current parenteral PPA therapy ( n = 20, 57%), followed by an improved clinical status on parenteral PPA therapy ( n = 8, 23%). The median length of transition was 36 h (IQR 24–48 h) and hospital stay was 3 days (IQR 2–6 days). Following transition, the cohort demonstrated stability in PAH‐specific risk scores and functional status. All patients survived to outpatient pulmonary hypertension follow up (median 5.5 weeks, IQR 1.4–9.6 weeks), and the majority were alive at 1‐year post‐transition ( n = 32, 91%). Based on these results, we conclude that transition from parenteral PPA's to selexipag can be done in the inpatient setting safely, quickly, and effectively.